Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies (Armodafinil)
Recruitment status was Recruiting
The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced Parkinson's disease (PD) and Lewy body disease (LBD).
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|
- EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks) [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
|Study Start Date:||December 2010|
|Estimated Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
The main aims of this study are:
1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia thalamocortical network, measured through the Electroencephalography (EEG) frequency analysis, are ameliorated by armodafinil.
Our main hypothesis is that armodafinil can restore the attention and improve cognitive disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01256905
|Contact: Sara Varanese, M.D.||212-263-4838 ext firstname.lastname@example.org|
|Contact: Jamika Y. Singleton-Garvin||212-263-7042||Jamika.Singleton-Garvin@nyumc.org|
|United States, New York|
|NYU Parkinsons and Movement Disorders Center||Recruiting|
|New York City, New York, United States, 10016|
|Contact: Sara Varanese, M.D. 212-263-4838 ext 3 email@example.com|
|Contact: Jamika Y Singleton-Garvin 212-263-7042 Jamika.Singleton-Garvin@nyumc.org|
|Principal Investigator: Sara Varanese, M.D.|
|Principal Investigator:||Sara Varanese, MD||NYU Parkinsons and Movement Disorders Center|